Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia (Q24200302)

6

0 references

Sheila A Fisher

1

object named as

Sheila A Fisher

0 references

author name string

Susan J Brunskill

2

0 references

Sarah Gooding

4

0 references

Onima Chowdhury

Cochrane Database of Systematic Reviews

5

0 references

publication date

21 August 2013

0 references

published in

0 references

cites work

Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

Oral deferiprone for iron chelation in people with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

Deferasirox for managing iron overload in people with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

Desferrioxamine mesylate for managing transfusional iron overload in people with thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

MRI of the liver and the pituitary gland in patients with beta-thalassemia major: does hepatic siderosis predict pituitary iron deposition?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Prolonged survival in patients with beta-thalassemia major treated with deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferoxamine-induced growth retardation in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Prevention of iron loading in transfusion-dependent thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Iron absorption and loading in beta-thalassaemia intermedia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Oral desferrioxamine in young patients with thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactic reaction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Ocular toxicity of high-dose intravenous desferrioxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactoid reaction.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival and causes of death in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The toxic effects of desferrioxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Early iron reduction programme for thalassaemia patients after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Immune function in patients with beta thalassaemia receiving the orally active iron-chelating agent deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Iron chelators for thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Combined therapy with deferiprone and desferrioxamine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Safety profile of the oral iron chelator deferiprone: a multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Oral iron chelation therapy for thalassaemia: an uncertain scene

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Reassessment of the Use of Desferrioxamine B in Iron Overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Academic freedom in clinical research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

A Randomized Controlled Study Evaluating the Safety and Efficacy of Deferiprone Treatment in Thalassemia Major Patients from Hong Kong

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Continuous desferrioxamine infusion by an infusor in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Erythropoiesis: Comparison of Cytotoxic Aldehyde Generation in Beta-Thalassemia Patients Chelated with Deferoxamine or Deferiprone (L1) Versus NO Chelation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Meta-analyses involving cross-over trials: methodological issues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The Effect of Ascorbic Acid Deficiency on Desferrioxamine-Induced Urinary Iron Excretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Light and shadows in the iron chelation treatment of haematological diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival and disease complications in thalassemia major.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Survival and desferrioxamine in thalassaemia major.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Introduction to The Olivieri symposium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Results of long-term iron-chelating therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Hepatic lipid peroxidation in vivo in rats with chronic iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferiprone and hepatic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Pituitary function in thalassemic patients and the effect of chelation therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/de

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021

Comparative effects of three iron chelation therapies on the quality of life of greek patients with homozygous transfusion-dependent Beta-thalassemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004450.PUB3

7 January 2021